Open AccessClinical and Immunologic Outcomes After Immediate or Deferred Antiretroviral Therapy Initiation During Primary Human Immunodeficiency Virus Infection: The Sabes Randomized Clinical Study
Author(s) -
Javier R. Lama,
Rachel A. Bender Ignacio,
Ricardo Alfaro,
Jessica Ríos,
Jorge A Gallardo-Cartagena,
Rogelio Valdez,
Carolyn Bain,
Karin Sosa Barbarán,
Manuel V Villarán,
Christopher D. Pilcher,
Pedro Gonzáles,
Jorge Sánchez,
Ann Duerr
Publication year - 2020
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciaa167
Subject(s) - interquartile range , medicine , adverse effect , randomized controlled trial , confidence interval , incidence (geometry) , antiretroviral therapy , immunology , viral load , pediatrics , human immunodeficiency virus (hiv) , physics , optics
In addition to demonstrated public health benefits on reducing transmission, it remains unclear how early antiretroviral therapy (ART) must be started after acquisition of human immunodeficiency virus (HIV) to maximize individual benefits.